Overview

Safety Study of Combined Chemotherapy and Endostar to Untreated Patients With Advanced Melanoma

Status:
Unknown status
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
Multicenter, double-blinding, randomized controlled, phase II clinical trial on combined chemotherapy of Endostar (Recombinant Human Endostatin) for untreated patients with advanced melanoma, To compare the efficacy and safety of Endostar combined with Dacarbazine and monotherapy of Dacarbazine for advanced melanoma
Phase:
Phase 2
Details
Lead Sponsor:
Simcere Pharmaceutical Co., Ltd
Treatments:
Dacarbazine
Endostar protein